Showing 4211-4220 of 5623 results for "".
- Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucomahttps://modernod.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/Sight Sciences announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma.
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r
- Regeneron Presents Encouraging Phase 2 Results for High-Dose Aflibercept 8 mg in Wet AMDhttps://modernod.com/news/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-amd/2480636/Regeneron Pharmaceuticals announced results from its phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (AMD). The resul
- Waldo Announces the Acquisition of Placid0, Maker of Eye Assessment Apphttps://modernod.com/news/waldo-announces-the-acquisition-of-placid0/2480632/Waldo announces the acquisition of Placid0, maker of EASY, an eye assessment system mobile application. Financial terms of the deal were not disclosed. The acquisition is the next step in Waldo’s movement to make eye care an essential part of everyday life, with bo
- Bausch Health Files for Solta IPOhttps://modernod.com/news/bausch-health-files-for-solta-ipo/2480629/Bausch Health Companies announced today that its wholly owned subsidiary, Solta Medical Corporation, has publicly filed for a proposed initial public offering (IPO). Solta, a provider of dermatology-focused lasers, has applied to list its common shares on the Nasdaq Global Select M
- Global Eye Health Body Unites With Novartis to Strengthen Eye Health in Africahttps://modernod.com/news/global-eye-health-body-unites-with-novartis-to-strengthen-eye-health-in-africa/2480626/The International Agency for the Prevention of Blindness (IAPB) has joined together with Novartis in a partnership to strengthen eye health in Sub-Saharan Africa. The new 3-year relationship will support effective policy dialogue, planning, and implementation of eye health services in the re
- Quantel Medical Launches C.STIM, a New Generation IPL System for Dry Eyehttps://modernod.com/news/quantel-medical-launches-a-new-generation-ipl-system-cstim/2480625/Quantel Medical announced the launch of C.STIM IPL system. Based on intense pulsed light technology, C.STIM is the new generation of IPL designed to treat the root causes of dry eyes: meibomian gland dysfunction, inflammation, and demodex. “Thanks to the unique
- Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operationshttps://modernod.com/news/outlook-therapeutics-expands-commercial-team-with-appointment-of-senior-vice-president-of-commercial-operations/2480623/Outlook Therapeutics, which is working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.
- Maintaining Transparency: Study to Focus on Causes of Cataractshttps://modernod.com/news/maintaining-transparency-study-to-focus-on-causes-of-cataracts/2480616/Researchers at the University of Arizona College of Medicine – Tucson are leading a study to identify the biological mechanisms that cause cataracts in the hopes that new, nonsurgical treatments may be developed. Nicholas Delame
- FDA Approves First Generic of Restasishttps://modernod.com/news/fda-approves-first-generic-of-restasis/2480612/The FDA has approved the first generic of AbbVie's blockbuster dry eye drug Restasis (cyclosporine ophthalmic emulsion) 0.05%, which generated $1.23 billion in U.S. sales last year. The agency said it approved the generic Restasis single-use vials from Mylan Pharmaceuticals, wh